The drugmaker was developing an mRNA-based COVID-19 vaccine using the same technology as Pfizer and Moderna’s COVID-19 vaccines. It hadn’t reached phase 3 trials.
Sanofi will pivot its mRNA research toward other infectious diseases, and the drugmaker has already begun early-stage trials on an mRNA flu shot, the Journal reported.
Sanofi is also creating a COVID-19 vaccine in partnership with GlaxoSmithKline. Thomas Triomphe, the head of Sanofi’s vaccine business, told the Journal that the company will continue developing that vaccine because it’s at a more advanced stage and could be useful as a booster shot. Results from its late-stage trial are expected this year.
The drugmaker is also trying to develop mRNA vaccines that can be stored at refrigerator temperatures rather than ultracold conditions, according to the Journal.
Read the full article here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
